Chemical enhancement of cisplatin cytotoxicity in a human ovarian and cervical cancer cell line-Reference-Cited by-同舟云学术

Chemical enhancement of cisplatin cytotoxicity in a human ovarian and cervical cancer cell line

Published:1990-09 Issue:3 Volume:38 Page:315-322
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Boike Guy M.,Petru Edgar,Sevin Bernd-Uwe,Averette Hervy E.,Chou Ting-Choa,Penalver Manuel,Donato Daniel,Schiano Michael,Hilsenbeck Susan G.,Perras James

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference47 articles.

1. The genetic origin of drug resistance in neoplasms: Implications for systemic therapy;Goldie;Cancer Res.,1984

2. Ovarian cancer treatment: Progress or paralysis;Young;Semin. Oncol.,1984

3. Chemotherapy of ovarian cancer;Ozols;Semin. Oncol.,1984

4. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: A Gynecologic Oncology Group study;Bonomi;J. Clin. Oncol.,1985

5. Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: A Southwest Oncology Group study;Alberts;J. Clin. Oncol.,1987

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New chalcone-tethered 1,3,5-triazines potentiate the anticancer effect of cisplatin against human lung adenocarcinoma A549 cells by enhancing DNA damage and cell apoptosis;Bioorganic Chemistry;2020-12

2. Synthesis of New N1Arylpiperazine Substituted Xanthine Derivatives and Evaluation of their Antioxidant and Cytotoxic Effects;Anti-Cancer Agents in Medicinal Chemistry;2019-06-25

3. Recent Synthetic Approaches Towards Biologically Potent Derivatives/Analogues of Theophylline;Journal of Heterocyclic Chemistry;2018-09-25

4. VIRTUAL TOXICITY AND DRUG LIKENESS OF NEWLY SYNTHESIZED METHYLXANTHINES WITH N1 ARYLPIPERAZINE MOIETY;CBU International Conference Proceedings;2018-09-25

5. Potential Use of Pentoxifylline in Cancer Therapy;Current Pharmaceutical Biotechnology;2018-07-10